Andrew Sinclair Biography and Net Worth

Director of Adicet Bio


Andrew Sinclair is on the board of Sierra Oncology, Inc., Soleno Therapeutics, Inc., Verona Pharma Plc and Adicet Bio, Inc. and Portfolio Manager & Partner at Abingworth Management Ltd. and Member of Institute of Chartered Accountants in England & Wales.

In the past Dr. Sinclair held the position of Research Analyst at Credit Suisse Securities (Europe) Ltd. and Research Analyst at HSBC Bank Plc (Broker).

He received an undergraduate degree from King's College London.

How do I contact Andrew Sinclair?

The corporate mailing address for Mr. Sinclair and other Adicet Bio executives is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. Adicet Bio can also be reached via phone at (650) 503-9095 and via email at [email protected]. Learn More on Andrew Sinclair's contact information.

Has Andrew Sinclair been buying or selling shares of Adicet Bio?

Andrew Sinclair has not been actively trading shares of Adicet Bio during the past quarter. Most recently, on Wednesday, December 8th, Andrew Sinclair bought 500,000 shares of Adicet Bio stock. The stock was acquired at an average cost of $14.00 per share, with a total value of $7,000,000.00. Learn More on Andrew Sinclair's trading history.

Who are Adicet Bio's active insiders?

Adicet Bio's insider roster includes Chen BA (), Jay Elliott (COO), Aya Jakobovits (Director), Chen Schor (CEO), and Andrew Sinclair (Director). Learn More on Adicet Bio's active insiders.

Are insiders buying or selling shares of Adicet Bio?

In the last twelve months, Adicet Bio insiders bought shares 5 times. They purchased a total of 4,016,000 shares worth more than $9,355,875.00. The most recent insider tranaction occured on January, 25th when Director Orbimed Advisors Llc bought 3,125,000 shares worth more than $7,500,000.00. Insiders at Adicet Bio own 29.5% of the company. Learn More about insider trades at Adicet Bio.

Information on this page was last updated on 1/25/2024.

Andrew Sinclair Insider Trading History at Adicet Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/8/2021Buy500,000$14.00$7,000,000.00View SEC Filing Icon  
See Full Table

Andrew Sinclair Buying and Selling Activity at Adicet Bio

This chart shows Andrew Sinclair's buying and selling at Adicet Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Adicet Bio Company Overview

Adicet Bio logo
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical trial for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-270 that is in preclinical stage for the treatment of renal cell carcinoma and potential solid tumor; and ADI-002, which is undergoing preclinical studies for the treatment of hepatocellular carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: $2.35
Low: $2.31
High: $2.40

50 Day Range

MA: $2.57
Low: $1.95
High: $3.38

2 Week Range

Now: $2.35
Low: $1.10
High: $7.50

Volume

534,078 shs

Average Volume

1,535,625 shs

Market Capitalization

$193.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.87